Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Orion, Webcast, Q3'26

By Inderes10/28/2026, 12:00 PM
Orion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tuukka Hirvonen
00:01 - 01:05

Good afternoon and welcome to the Orion Q3 2026 conference call and webcast. My name is Tuukka Hirvonen and I am the Head of Investor Relations here at Orion. I am here today with our CEO, Liisa Hurme, and CFO, René Lindell. We will start shortly with Liisa's presentation, after which you will have the possibility to ask questions of the management. We will first take questions from the conference call lines, and afterwards we will turn to the webcast chat questions. So you may type in your questions utilizing the webcast chat function. Before going through the disclaimer for our Finnish-speaking viewers, a CEO interview in Finnish will be published later today on Orion's website regarding the results. And now, before letting Liisa start, a quick reminder about the disclaimer and forward-looking statements. And with this, it is my pleasure to hand over to Liisa.

Liisa Hurme
01:05 - 19:05

Thank you, and welcome to the Orion Q3 2026 webcast. Once again, we have delivered a strong quarter with improved sales and profitability growth. Nubeqa continued to be the growth driver, but all business units across our branded products also showed healthy growth. We are proud to share that we have proceeded with our first biological molecule into Phase I, and this is a very important milestone for Orion R&D. Another very important piece of information on the R&D side is our progress. The interim results of the DASL-HiCaP study demonstrated a 58% reduction of the risk of metastasis or death with darolutamide and androgen deprivation therapy and radiotherapy versus a placebo and androgen deprivation therapy and radiotherapy. And this week, after the quarter, we also on Monday announced changes to the Orion Executive Team to continue proceeding with our strategy. And now, let us turn to the numbers. Our net sales increased by 28%, totaling 542 million euros, and our operating profit had a growth of almost 74% and totaled 210 million euros. And our earnings per share grew accordingly. And when we look at the net sales, we clearly see that Innovative Medicines, with Nubeqa, drives our net sales growth with 130 million here. And branded products, of course, with smaller numbers, but a significant growth in branded products of 7.4 million. And this quarter, generics had a bit of a tough time, down 4.6 million. But we have had a very tough comparative period from last year. Animal health was more or less on par. And Fermion reported excellent deliveries to our customers. Regarding our operating profit. Even more clearly, royalties are driving this with 104 million. And maybe the other figure that I would like to point out here are our fixed costs of 22.3 million, which is exactly as we expected it to be. We have been communicating and executing our R&D pipeline projects simultaneously, so all our R&D projects are proceeding. Thus, this results in higher fixed costs. And they are also partly due to the increased sales and marketing costs. Changes in sales volume were also very positive at 4.9 million, and changes in prices, COGS, and product mix contributed 2.6 million, all on the positive side. And now turning to year-to-date numbers from January to September, we see very similar figures, with 24% growth totaling 1 billion and almost 66% growth in operating profit, a bit over 500 million during the first nine months, and again, earnings per share following that growth. And now I turn to separate divisions where we can look at the quarter and also the year-to-date numbers. And here in the dark blue you can see Nubeqa royalties and product sales, 280 million in the third quarter, and then some other services and sales in the lighter blue here. And during the first nine months, net sales reached 662 million. Once again, I would like to point out that on the right side, you can see how the dynamics evolve during the year, as we always start from a lower level of royalty in the first quarter of every year. It is good to remind you here that we reached the highest royalty rate in the second quarter. So the growth that we are seeing here with Nubeqa is an absolute growth of royalties, meaning absolute growth of sales at market. And we had royalties of 222 million and tablet sales of 58 million to Bayer during the Q3. And a very healthy growth for branded products during Q3, almost 11% growth with a portfolio of Easyhaler products where budesonide-formoterol is clearly the growth driver. Our CNS portfolio shows growth there as well. This time, not entacopone growth, but rather growth of some of our new CNS products that we have discussed here earlier. For example, for migraine and some additional products for Parkinson's disease patients. And the fastest growth segment was again Women's Health. The same trend can be seen in the first nine months' figures. Generics and consumer health had, as I said already in the beginning, a quite rough starting point. A quite rough starting point. Comparative period from last year. So quarter three figures are down 3.4%. But still, I think it is a very healthy business here. And when you then look at year-to-date numbers, I think you can say it is on par. We are on the same level as last year, and this is due to the slight decline in the generic prescription drugs. However, the consumer health business is proceeding as it did last year. No decrease has been seen there. And I am happy to report that we have signed a license agreement with the Chinese company Qilu to commercialize IV pembrolizumab, which is a biosimilar of Keytruda across Europe. And the expected launch of this product would be in the early 2030s. Animal health is more or less on par. During Q3 compared to the previous year, we see slightly lower figures in the year-to-date numbers. And Fermion. Great numbers. I already mentioned this at the beginning. And let's remember this is really external deliveries. And this is mainly coming from contract manufacturing and, actually, contract development and manufacturing services for both API and finished dosage forms. So when we report Fermion sales, it includes also contract manufacturing and development for finished drugs. I am happy to report that we are ramping up, as we speak, the plant three in Hanko. That was the plant where we had the water damage in early July. And now we are ahead of schedule and clearly and solidly ramping up that plant, and all the other plants have already been ramped up after the maintenance break as planned. Our top ten products. I believe the order remains the same as last time. And you can see the almost 70% growth for Nubeqa, almost 7% growth for Easyhaler, and a slight decline for Entacapone. This is due to price pressure almost all over the world. It is a global product and we see price decreases in different parts of the globe. Volumes, however, keep on growing all the time. And for the Divina series, you can see almost 47% growth. And I think this is amazing. It is great news for women globally that these treatments are available. And when you look at the animal health numbers, I think part of the explanation is here. It is about the timing of shipments; the sedative shipments again have been a bit later than we expected. It might be just a one-day difference between quarters. So here we see a negative number. And I think the main message on this slide is that almost half of Orion's revenue comes from innovative medicines after the first nine months, meaning Nubeqa royalties and product sales. The clinical development pipeline DASL-HiCaP interim results were reported by Bayer at ESMO. Very positive results, as I already mentioned. And we are also happy to report on the new molecule ODM-216. That is our first biological molecule, a large molecule in our pipeline. And we have a study called BiCIDES going on with this bispecific antibody. And it is targeted to advanced solid tumors. I cannot and will not share any more about specific indications at this stage. Sustainability is an important priority for us. It is not only an item on our agenda that we need to do. We perform every day to take good care of our value chain, from sourcing the starting materials and intermediates, sourcing APIs, sourcing drugs from other companies, to distributing and selling the drugs to our customers. All this is very important. You can see that reflected in the four pillars of our sustainability agenda. And of course, how we are seen by the external environment validates that we are doing well. And I think the recent news is that we have now achieved the silver level by EcoVadis. And of course, we continue the good work and aim even higher. Based on a strong first nine months, very good royalties, and a positive outlook for the rest of the year. We upgraded our financial outlook for this year so that our net sales range is from 2,070 million to 2,140 million. Our range for operating profit is from 730 million to 790 million. And then after the third quarter, as I mentioned earlier this week, we announced changes in our executive team and in our divisional structures. We have not changed our strategy. On the contrary, our strategy has become a necessity. In the beginning, when we launched the strategy in 2023, it was an aspiration for Orion to become a more global company from a European-based pharmaceutical company, to go out to the world both commercially and by building R&D capabilities around the world where they are needed and where they are available. And we have more or less accomplished this. The first three years, we've strengthened our presence in Europe with all our key brands, and we continue to do that. We have established our sales operations in Japan, which actually also serves as a platform for our clinical studies, for example, for ODM-216. So now for the first time, we are running our own studies outside Europe. But now we are moving to the next stage of this strategy. And that means that we need to sharpen up and focus even more on our strategic assets. And thus, we have made some changes in our organization. We have created a new role, a Commercial Executive Vice President for International Commercial Operations, for Mr. Hao Pan is leading this organization. He has been a member of the Orion Executive Team since early 2023. And now he is responsible for all ex-U.S. Commercial operations, as all the US operations are reporting and are headed by Berkeley Vincent. He is also responsible for the Innovative Medicines. The other change is thatMr. Juhani Kankaanpää, who has been heading our global operations, which means all our manufacturing sites, sites for finished goods for APIs, company procurement, and supply chain, also now heads our Generics and Consumer Health division. And we also welcome a new member to our executive team, Mr. Henri Salokangas, as an Executive Vice President for Branded Products, continues in that role. But we have added a hospital business to the respiratory, women's health, and CNS businesses. And why do we do this? I think it underlines the fact that we are becoming more global. We definitely focus on our key brands in branded products. We are building our Europe-wide hospital business. We have the existing products there. Simdax. Dexdor. Some biosimilars that we are already selling across Europe. As I already mentioned, we have made another agreement for new biosimilars. We have made several of those. And we also have value-added hospital products like recombinant albumin under development by our suppliers. So we are building that business unit under the branded division. Then again, the generics business is really about supply, price, and service level. And thus, it is now combined with our global operations, where the bigger picture of that part can be taken care of. And then, a very long-term member of the Orion Executive Team, Mrs. Satu Ahomäki has decided to leave the company after an admirable 34 years of service for Orion Pharma and 19 years on the Orion Executive Team. I take the opportunity here to thank her for all her commitment and work during those years. Her legacy will remain. I think she has worked with all the business divisions and left her mark on all the businesses that we do, and we will continue her precious work. And here you can see our upcoming events. And I thank you for your attention. I believe it is time for questions and discussions.

Tuukka Hirvonen
19:06 - 19:31

Thank you, Liisa, for the presentation. As I said, now it is time for Q&A. As I said, we will start with the conference call lines. But also, remember that you have the opportunity to type in your questions through the webcast chat. But at this point, I would like to hand over to the conference call. Operator. Please go ahead with the questions.

Operator
19:31 - 19:48

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six. Six on your telephone keypad. The next question comes from Alex Moore from Bank of America. Please go ahead.

Alex Moore
19:50 - 20:18

Hi. Thanks for taking my questions. I have three questions, all regarding Nubeqa. I'm afraid so. The first question is regarding Nubeqa royalties. Following up on your comments at Q2, is it still reasonable to assume royalty growth in the fourth quarter should be roughly in line with Nubeqa in-market sales, given you've already reached the maximum royalty tier and there is consensus that this assumption of roughly 10% sequential growth for in-market sales is broadly consistent with the assumptions underpinning your updated guidance?

Liisa Hurme
20:21 - 20:23

Yes, maybe I will take the royalty question.

René Lindell
20:23 - 20:55

Yes. I mean, the maximum royalty percentage has been reached already. As Liisa Hurme said in Q2. So from that perspective, naturally, the royalties then would be directly proportional to the market sales that Bayer would then report to us. And then, of course, what the growth is in Q4. We will then see, but you can see our guidance and outlook and estimate from there as well. What might be the potential range for Nubeqa?

Alex Moore
20:57 - 21:22

Okay, great. So, second question, just on tablet sales; I think tablet sales declined about 10% sequentially in the quarter. Can you confirm whether this was mainly due to the maintenance break. And I think your commentary at Q2 implied you typically back up to full production in the fourth quarter. So, should we expect year-on-year growth for tablet sales in Q4 to be roughly similar to what we saw in the second quarter?

Liisa Hurme
21:23 - 21:56

Yes, there usually is a bit of a fluctuation due to the maintenance break, but I think the change now between the Q2 and Q3 is just a normal variation of how we ship out the tablets from Fermion to Orion, and then from Orion Pharma to Bayer. So I don't think there is anything specific, and there might still be variation between the quarters. I don't know, is there something you want to add?

René Lindell
21:56 - 22:16

No. It's like you said that there will always be fluctuations depending on the shipments. And those can be quite big as we ship in large batches. So, it's hard to say if the next quarter will be up or down. So I think the general trend, if you look at the year, is upward and in the right direction, of course.

Alex Moore
22:18 - 23:10

Okay, great. So, this is my last question, which is more on your long-term ambition for Nubeqa. So, just on the recent positive interim readout for DASL-HiCaP, I think you've previously said that your greater than €1 billion guidance for Nubeqa sales by the end of the decade includes potential early line expansion. Can you give any color on what sort of risk adjustment was used relating to the DASL-HiCaP opportunity in that guidance? Given you appear to reach that milestone for Nubeqa sales either this year or next, based on current indications alone and the quite large potential addressable population for DASL-HiCaP, does this not imply meaningful upside to the lower end of that target? Therefore, what specifically needs to occur before you can de-risk and potentially quantify the upside to your long-term Nubeqa revenue guide?

Liisa Hurme
23:11 - 24:06

Well, I may start and then continue on our guidance; as our partner has said, and as we have stated many times, we need positive results from these early-line studies to fulfill the full potential that Bayer has projected for Nubeqa. And we all know that they have said that this will be the biggest product that they have ever had, which means that it will be around €5 billion. So these DASL-HiCaP positive interim results, let's remember, are already included in those numbers. I think the question regarding if we are able to then update our guidance is a bit of a separate one. And it's not. I don't think it is time for that now. I think that might come later, but right now we follow that guidance.

Alex Moore
24:09 - 24:10

Thank you very much.

Operator
24:12 - 24:16

The next question comes from Anzi Rossi from SEB. Please go ahead.

Anzi Rossi
24:18 - 24:47

Yes. Hi, Juhani. Thank you for the presentation. First question on your expenses. Of course, we know that the research and development and also sales and marketing expenses were clearly higher in Q4 last year compared to the other three quarters of that year. So do you think that these expenses will actually increase or decrease in Q4 this year compared to the fourth quarter of last year?

René Lindell
24:49 - 25:48

Yeah. We are not giving guidance specifically on Q4 expenses and how those will pan out. So we still maintain our full-year guidance. But I think overall, last year had certain dynamics when it came, especially to the R&D expenses that did jump at that point in time. But I still would encourage you to look at the full year and, from that, deduce the full-year potential expenses that we will have. But I mean, nothing material comes to mind in terms of Q4 being very different from the others this year. I mean, although sometimes in Q4, there are questions that. How do we book R&D expenses? Depending on how the projects are actually progressing. And that will then have a certain variation, which of course also is partly reflected in our outlook, although in a much minor component than the potential Nubeqa scenarios.

Anzi Rossi
25:51 - 26:12

Okay. Understood. And then, about Nubeqa tariffs. So can you give us an update on your estimates? And also, maybe as you mentioned, this contract manufacturing in the U.S. Can you mitigate this impact with this kind of agreement in the future?

René Lindell
26:13 - 27:15

Yes. On tariffs, there is really no change from where we were last quarter. I mean, basically, if you look at what we know, those tariffs should be operational and applied from the beginning of October onwards. So in a way, we do estimate that there is some tariff impact in Q4, at least according to what we know. In the end, we will only see that once we actually see when those are booked at the customs and we see how those are treated. So yes, we do assume some tariffs, but they are quite minor for Q4. And we will basically have to wait and see how those really are calculated in the end. And for the second part of the question regarding API manufacturing in the U.S., naturally that could have an impact on tariffs, but that is also something to be seen. So, hopefully, it will have an impact on that. But it also impacts our overall global supply of darolutamide.

Liisa Hurme
27:16 - 27:25

And I think that is the most important thing that we now have. Again, we have another facility where we manufacture darolutamide API.

Anzi Rossi
27:28 - 27:46

Okay. Got it. And the final question from me. You mentioned that there are some new products entering the clinical phase in the coming months. So could you comment on what kind of molecules these are or provide any additional color on them? Thanks.

Liisa Hurme
27:47 - 28:13

All right. I guess you are referring to the upcoming period. I already mentioned ODM-216, the bispecific antibody. But yes, I think I've been bullish enough already early this year to say that we will bring at least one biologic into our clinical pipeline. But I might be even more bullish here and say that there might be another new phase one program even during this year.

Anzi Rossi
28:17 - 28:19

Okay. Understood? Thank you so much.

Operator
28:20 - 28:25

The next question comes from Sami Sarikamis from Danske Bank Markets. Please go ahead.

Sami Sarikamis
28:27 - 28:53

Hi. I have three questions. We will start with Nubeqa. You announced today that you are going to be using contract manufacturers going forward. Can you elaborate on your thinking regarding what has changed? Is this related to potentially higher peak sales, risk management, or US tariffs? And how do you think this will impact Nubeqa gross margins in the long run?

Liisa Hurme
28:55 - 29:32

Good question. Definitely. When we see that the volumes have been growing much faster and higher than originally estimated, it is important to manage your supplier risks. And that means that you need to have several site suppliers supplying the key ingredients like darolutamide API. And now we have two. We have one in Hong Kong, one in Germany, and then one will be in the United States. It is really to secure the volumes and manage our risks.

Sami Sarikamis
29:36 - 29:43

Okay. And what about the impact on Nubeqa gross margins? When will some of that capacity be taken into use?

Liisa Hurme
29:44 - 29:47

I don't think I can comment on that.

René Lindell
29:47 - 30:19

Yes, of course. I mean, if you look at it, we will most likely be manufacturing the bulk of the API at the Hong Kong site, where we have been doing that for years. And of course, we are efficient; that I can say. So there will be some additional gross margin impact. Typically, when you build resilience, there is, of course, some price to that. But that resilience is worth paying for, because now you have more flexibility in how you use the sites and what volumes you need at any point in time; in the end, the impact will be marginal.

Liisa Hurme
30:20 - 30:21

Exactly.

Sami Sarikamis
30:23 - 31:02

Okay. Then my second question would be on operating expenses. If we look at this here, R&D expenses have grown 20% since the marketing by roughly 10%. You are planning to become a more global company. So, what kind of growth rate in operating expenses are you thinking? Is it still going to be below top-line growth? Or could it be that, in the coming years, there will be margin erosion from your investments into the Orion platform?

René Lindell
31:04 - 32:15

Yes, maybe I can answer that. So that really depends on how our products move forward in the clinics and what the success rate is. So we are investing in R&D. We know that our pipeline is getting better and we should continue that. So that means also that the R&D spend as a percentage of revenue might in some years grow faster than the top line. Of course, our top line has been growing fast enough that even as we have been growing R&D by 20%, the top line has been slightly above that. So it can be lower, it can be higher, but it really will depend on the clinical pipeline and the sales and marketing, as well as the timing of the products we have coming into the market? There are some investments you need to do before the sales happen, especially on the innovative side. So then you need to invest before you see the sales. And then you could have, at least in the short term, an increase in sales and marketing expenses faster than the sales for that specific product or business division. But over time, that should catch up again. So there could be fluctuations. But there is nothing systematic that we can point out at this point.

Sami Sarikamis
32:17 - 32:34

Okay. And then my final question would be on the updated guidance. The range is still pretty wide going into the last quarter of the year. So can you elaborate a bit on the reservations and uncertainties you still have for the rest of the year?

René Lindell
32:34 - 33:14

Yeah. Yes, that is quite clear that the biggest reason for a wide range still is Nubeqa. As it is Q4, we have the maximum royalty rate and we have a fast-growing product. And Q4 is thereby estimated to be our best quarter also for Nubeqa. And there's a fairly broad range where this year could end up. I think the rest of the businesses have much smaller ranges and are, in a way, easier to predict, but Nubeqa, with such a growth curve and momentum, naturally gives quite a broad range still at this point, even though we narrowed it down a little bit in this latest outlook.

Sami Sarikamis
33:17 - 33:19

Okay, thanks. I don't have any further questions.

Operator
33:21 - 33:25

The next question comes from Sean Homma from Jefferies. Please go ahead.

Sean Homma
33:26 - 33:53

Hi there. Thank you for taking my questions. I have three, if I may. So firstly, just on Nubeqa royalties for this quarter. At first glance, they seem a little bit soft versus consensus expectations. Is there any particular reason for this, such as potentially a correction for your estimate for the last month of the last quarter? That is my first question. I will ask the other two later. Thanks.

René Lindell
33:53 - 34:23

Yeah. Of course, there is always a matter of estimation when we go into a quarter, as we have discussed quite often, both on the first incoming month and the last month; that can be one source of why, later, when you compare to any Bayer number, you can see a discrepancy. But of course, at this point in time, I am not commenting on any expectations regarding that number, but as I said, it is an estimate. The last month.

Sean Homma
34:25 - 34:43

Understood. Thank you. And then my next question is, how do you anticipate Nubeqa's underlying market trajectory to develop through this quarter and then also into 2027, particularly with enzalutamide generics expected to come online potentially end of next year into 2028?

Liisa Hurme
34:45 - 35:30

Well, I don't think we are in a position to give any guidance regarding Nubeqa growth rate for 2027 or even the fourth quarter. I think that's a good question to ask Bayer. I think so. So what we are always referring to is the fact that Bayer has said this will be the biggest product they have ever had. To reach that, we will need to be successful in all the studies that are ongoing now. And fortunately, we have seen good interim results on DASL-HiCaP. So I think it's all on the positive side, but I wouldn't go and predict any definite numbers.

René Lindell
35:30 - 35:45

No, I think it is easy to say that the general direction is that we have quite far to go still to reach that peak year. And from that perspective, one could say that the general momentum of growth will continue for a few years to come.

Sean Homma
35:47 - 36:02

Thank you so much. And then just finally, for me, as you mentioned, DASL-HiCaP, how are you thinking about your option for that indication? I mean, in terms of an exercise timeline, just because of course, the data are pretty encouraging at ESMO over the weekend.

Liisa Hurme
36:03 - 36:35

Indeed, the data was very encouraging. And let's remember it is an IIS study. So it is an investigator-initiated study. And we have an opt-in possibility. We are now planning and have an understanding with Bayer that we would use that opt-in if and when they submit a marketing approval application. But that will, of course, be somewhere in the future.

Sean Homma
36:36 - 36:37

Thank you so much.

Operator
36:39 - 36:51

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Matti Korhola from OP Corporate Bank. Please go ahead.

Matti Korhola
36:53 - 37:27

Hello and good afternoon on my behalf as well. I still would like to ask about your guidance. So in your guidance, you are expecting a strong Q4 result. The strength should come from gross margins as the sales guidance did not increase, or increased less than the EBIT guidance. So where is the strength in gross margins coming in Q4 compared to Q3? As you should already be at the highest royalty rate. Really?

René Lindell
37:29 - 37:43

Yeah. I think the only quick answer I can provide is that, of course, the share of Nubeqa royalties will be larger than before in Q4. And that strengthens the overall gross margin and gross profit for the whole company.

Matti Korhola
37:45 - 37:52

But there are no production costs lower in Q4 compared to Q3 because of the name.

René Lindell
37:52 - 37:55

Nothing. Nothing. Nothing like that. No.

Matti Korhola
37:57 - 38:30

Okay. Okay. Then I think the things that still need to be cleared, but the value that, for example, the US Customs is using is quite close to what Bayer is referring to. As I said, I'm just thinking whether the duty will be really calculated from some sort of sales price, or is there any kind of indication, as it has been almost one month since they have been collected?

René Lindell
38:32 - 38:50

No, at the moment there is not. There is a range of scenarios for how this could be calculated. We will see when that is actually done. So I think I have nothing new that we can report on tariffs at this point in time.

Matti Korhola
38:52 - 39:12

Okay. And then one final question. So, regarding this Nubeqa contract manufacturing. So is it the case that you are producing the API there, but the tablet or the formulation is still done in Espoo, or how is the whole chain changing or going forward?

Liisa Hurme
39:13 - 39:29

I assume you are talking about Nubeqa. Yes, we are manufacturing the API. Yes, in Hong Kong and in the other sites that we already discussed. And then the tablets are manufactured at our manufacturing site.

Matti Korhola
39:31 - 39:33

Okay. So the final products are still being shipped from our facilities.

Liisa Hurme
39:33 - 39:34

Yes.

Matti Korhola
39:35 - 39:36

Yes. Thank you.

Operator
39:41 - 39:43

There are no more questions at this time.

Tuukka Hirvonen
39:45 - 40:03

All right. Thank you. Operator. Then we turn to the webcast questions. We have a few of them. Let's start with one coming from Iris Hummast from Carnegie. So what is your current plan for ODM-212? Do you plan to develop it yourself or are you looking for a partner before the phase three study?

Liisa Hurme
40:03 - 40:23

Right now, we are planning to carry out the studies by ourselves. We are in phase two, and those studies we are carrying out by ourselves. As it seems now, both indications, both the AR and the mesothelioma, are such that we can conduct those phase three studies by ourselves.

Tuukka Hirvonen
40:25 - 40:46

Thank you, Liisa. Then moving on, one question regarding animal health. So could you please provide further details on the animal health performance, specifically regarding the timing of shipments and any other contributing factors that may exist? Do you expect better growth from this division for the remainder of 2026? And how about going into 2027?

René Lindell
40:47 - 41:31

Yes, maybe I will start there. So. So, of course for this year, I think there are some geopolitical headwinds in that business, especially in the livestock business, which have been delaying shipments, especially to the Middle East and Africa. We all know that can take some time. That is one reason why we are a bit behind in net sales. But other than that, if those shipments go through and other things that are planned for the full year, I think this year still has the potential to be at a good level. And for next year, we will have to see when we provide the guidance for the outlook.

Tuukka Hirvonen
41:31 - 41:32

Yes, exactly.

Liisa Hurme
41:32 - 41:43

It may be. In other words, the sales would materialize. The demand is there, and there would be sales. But there has really been some struggle on the Middle East and African front.

Tuukka Hirvonen
41:44 - 41:57

Great. Then a follow-up from Iris regarding DASL-HiCaP. Can you comment on Bayer's regulatory plans following the DASL-HiCaP interim readout? And do you expect FDA discussions to begin soon?

Liisa Hurme
41:58 - 42:21

What we know from Bayer is that they are planning to have discussions at some point with the FDA, and we will then see where that leads regarding the registration and marketing approval application, but we do not know more than that. But with such encouraging results, of course, we all hope that everything will go well.

Tuukka Hirvonen
42:24 - 42:45

Then another question. This comes from Becca. Given that Nubeqa continues to drive such a massive share of revenue and operating profit, how are you managing the concentration risk? Specifically, how is the current cash flow from Nubeqa being deployed into the R&D pipeline to ensure a sustainable growth engine before we eventually approach the patent cliff?

Liisa Hurme
42:46 - 43:32

That is a good question. I think that is one of the major activities in our strategy currently, as we are developing new molecules. We are increasing our R&D budget year on year, pushing new products into Phase I, Phase II, and eventually to Phase III, while also using that cash to build new capabilities in R&D and on different commercial fronts. And that is why we own R&D and own capabilities. But of course, we are also constantly looking for new products and assets to be in-licensed or acquired. So there are a lot of activities ongoing to prepare for the 2030s and 2040s.

Tuukka Hirvonen
43:33 - 43:56

Thanks, Liisa. Then a couple of questions also from Pekka relating to the use of AI. So there are a couple of questions, but maybe I can sum them up in one question. So how is Orion currently leveraging artificial intelligence, quantum computing, and machine learning in R&D. In which areas are you deploying those?

Liisa Hurme
43:57 - 45:48

I will start with R&D, especially in early-stage research where we handle huge amounts of information; we go through not millions, but sometimes billions of molecular structures when we are trying to find a solution for a certain disease or a specific pathway that will have an effect on a cancer tumor. Other diseases like Parkinson's disease. And then the quantum capacity, of course, solves something, but also we use different artificial intelligence tools that we have found across the world. So we work with several companies in the US, in the UK, and here in Finland to find new ways and technologies to speed up that phase in the development. We have already seen that. We have been able to halve the time in the discovery and research. So there is a lot going on and it's by no means a new thing for us, but we've been doing that almost for ten years now. We already see good results. And then, of course, when you get to the clinical studies, you can also use artificial intelligence in many ways. When you are determining or defining your clinical patient population. So you can use these kinds of digital twins to test your molecule and try to define what would be the best patient population for your studies. And between each clinical stage, from phase one to phase two and phase three. Of course, AI brings tools to speed up the transition from one stage to another.

Tuukka Hirvonen
45:49 - 46:03

Thank you. And currently, the final question from the chat is, how should we think about Nubeqa® exclusivity beyond 2033, particularly in light of the later expiring US patents?

Liisa Hurme
46:03 - 46:20

Well, the basic patent that expires in 2033 is the one that will hold, I think. And that is the one on which generally all the pharmaceutical companies rely. And in this industry, we rely on it.

Tuukka Hirvonen
46:23 - 46:33

So, basically, there are others. But we rely on the 2033 date. So it's too early to speculate on any results from other patents. We will have to wait and see.

Liisa Hurme
46:33 - 46:34

Yes.

Tuukka Hirvonen
46:35 - 46:45

All right. Thank you. Now, we have exhausted all the questions both online and from the conference call line. So it is time to wrap up, and maybe the final words from Liisa.

Liisa Hurme
46:46 - 47:01

Thank you for your attendance. And it was our pleasure to report the strong Q3 results. And we are really looking forward to this ongoing quarter to finalize this good year. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…